Leadership & People
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Executives On The Move: Sypre Therapeutics, Evelo Biosciences, Amylyx Pharmaceuticals And More
Recent executive moves in the industry include changes at the top at Spyre Therapeutics, Neopharmed Gentili and CytoDyn.
Novartis Has A New Goal: $2bn Peak Sales Per Product
The company said during its R&D day that it has culled its pipeline to 103 clinical stage assets, choosing to focus on drugs that could be big blockbusters.
.jpg?rev=e7c1bbd0588a422a9f8201efc1abb421&w=350&hash=2C4A299CB7964738CF2E432069BC58BA)
Astellas India MD On Action-Packed Run Ahead, Breaking The Glass Ceiling
In an interview with Scrip, Astellas’s India chief outlines how the Japanese company expects to build out its operations in the country, with a flurry of key launches in the wings. She also shares vignettes of her own career path, which has not been a bed of roses.
Scrip Awards Lifetime Achievement Winner Jeremy Levin Urges Pharma To Put Humanity First
In accepting Scrip’s Lifetime Achievement Award, Ovid Therapeutics’ CEO called on pharma to show responsible leadership and live up to its potential to do good for society.
Executives On The Move: New CEOs at Novavax, Homology Medicines, Race Oncology And More
Recent moves in the industry include internal rejigs at Homology Medicines, Virpax Pharmaceuticals, CytoDyn and Applied Therapeutics, plus new board members at Neuroscientific Biopharmaceuticals.
Executives On The Move: New C-Suite Changes At Amneal Pharmaceuticals, Lexicon Pharmaceuticals And Amicus Therapeutics
Recent moves in the industry include changes at the top at Amneal Pharmaceuticals, plus new CEOs at Incendia Therapeutics and Nereid Therapeutics.
Norway’s Nykode Eyes NASDAQ As Pipeline Advances
CEO Michael Engsig tells Scrip that his well-capitalized company has ambitious plans for US expansion and is looking to set up an autoimmune diseases arm to add to its oncology efforts.
Novartis Casts Nets Globally To Snap Up Best Assets
The Swiss major’s business development chief Susanne Kreutz tells Scrip that geography is no barrier for her team in the search for promising licensing deals or bolt-on acquisitions.
Executives On The Move: C-Suite Changes At Astellas Pharma Plus New CEOs For Three Firms
Recent executive moves in the industry include changes at the C-suite at Astellas Pharma, plus new CEOs at Y-mAbs Therapeutics, Ocuphire Pharma and Neopharmed Gentili.
The Next Frontier In Obesity: Better, Not More, Weight Loss
R&D leaders from Novo Nordisk, Lilly, Boehringer Ingelheim and others discussed what some of the advances could be in the next generation of obesity medicines.
BioMarin’s Bienaimé To Retire With Sales And Earnings Growth On Track
Genentech CEO Alexander Hardy will succeed Jean-Jacques Bienaimé, who has led the rare disease specialist for 18 years. Gene therapy Roctavian has gotten off to a slow commercial start.
Executives On The Move: Change At The Top For BMS Among other New CEOs
Recent executive moves in the industry include new CEOs at Viridian Therapeutic, Opthea and Gyre Therapeutics, while Bristol Myers Squibb confirms its new leadership.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.